- Protocol Short Name and Number: TRIuMMpH, 2304
- Protocol Long Name: Phase II Randomized Trial of Immunotherapy After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Newly Diagnosed Multiple Myeloma (TRIuMMpH Trial)
- Protocol v1.0: Pending
- ICF: Pending
- FAQ’s: Pending
- Key Personnel
- BMT CTN #2304 Co-Chair: Saad Usmani, MD, MBA
- BMT CTN #2304 Co-Chair: Binod Dhakal, MD, MS
- BMT CTN #2304 Protocol Officer: Othman Akhtar, MD; Marcelo C Pasquini, MD, MS
- BMT CTN #2304 Protocol Coordinator: Bryan Reed, Erica Anderson